Li Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1120335/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNA-185 modulates CYP7A1 mediated cholesterol-bile acid metabolism through post-transcriptional and post-translational regulation of FoxO1. Atherosclerosis, 2022, 348, 56-67.	0.4	9
2	Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. Npj Biofilms and Microbiomes, 2021, 7, 36.	2.9	81
3	Antisense microRNA185 loaded liposome for efficient inhibition of the hepatic endogenous microRNA185 level. European Journal of Pharmaceutical Sciences, 2021, 161, 105803.	1.9	6
4	Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents. Bioorganic Chemistry, 2021, 113, 104994.	2.0	13
5	Identification of Novel Compounds Enhancing SR-BI mRNA Stability through High-Throughput Screening. SLAS Discovery, 2020, 25, 397-408.	1.4	2
6	Butyrate protects against highâ€fat dietâ€induced atherosclerosis via upâ€regulating ABCA1 expression in apolipoprotein Eâ€deficiency mice. British Journal of Pharmacology, 2020, 177, 1754-1772.	2.7	96
7	A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α. EBioMedicine, 2020, 52, 102650.	2.7	36
8	Relationship between porcine miR-20a and its putative target low-density lipoprotein receptor based on dual luciferase reporter gene assays. Asian-Australasian Journal of Animal Sciences, 2019, 32, 922-929.	2.4	6
9	Salvianolic acid B alters the gut microbiota and mitigates colitis severity and associated inflammation. Journal of Functional Foods, 2018, 46, 312-319.	1.6	42
10	Low-density lipoprotein upregulate SR-BI through Sp1 Ser702 phosphorylation in hepatic cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1066-1075.	1.2	8
11	High-density lipoprotein-based drug discovery for treatment of atherosclerosis. Expert Opinion on Drug Discovery, 2015, 10, 841-855.	2.5	8
12	microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator. Atherosclerosis, 2015, 243, 523-532.	0.4	60
13	Advances in the role of microRNAs in lipid metabolism-related anti-atherosclerotic drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 977-990.	2.5	5
14	MicroRNAs 185, 96, and 223 Repress Selective High-Density Lipoprotein Cholesterol Uptake through Posttranscriptional Inhibition. Molecular and Cellular Biology, 2013, 33, 1956-1964.	1.1	144
15	Salvianolic acid B inhibits macrophage uptake of modified low density lipoprotein (mLDL) in a scavenger receptor CD36-dependent manner. Atherosclerosis, 2012, 223, 152-159.	0.4	72
16	Design, Synthesis and Biological Evaluation of Hydroxamic Acid Derivatives as Potential High Density Lipoprotein (HDL) Receptor CLA-1 Up-Regulating Agents. Molecules, 2011, 16, 9178-9193.	1.7	5
17	Synthesis and structure–activity relationship of N-(2-arylethyl) isoquinoline derivatives as human scavenger receptor CD36 antagonists. European Journal of Medicinal Chemistry, 2011, 46, 1066-1073. 	2.6	9
18	Discovery of Antagonists for Human Scavenger Receptor CD36 via an ELISA-Like High-Throughput Screening Assay. Journal of Biomolecular Screening, 2010, 15, 239-250.	2.6	47

LI WANG

#	Article	IF	CITATIONS
19	How can high-throughput screening deliver drugs to treat atherosclerosis?. Expert Opinion on Drug Discovery, 2010, 5, 1175-1188.	2.5	5
20	Identification of trichostatin A as a novel transcriptional up-regulator of scavenger receptor BI both in HepG2 and RAW 264.7 cells. Atherosclerosis, 2009, 204, 127-135.	0.4	28
21	Characterization of the Isoflavone Pratensein as a Novel Transcriptional Up-Regulator of Scavenger Receptor Class B Type I in HepG2 Cells. Biological and Pharmaceutical Bulletin, 2009, 32, 1289-1294.	0.6	12